Gnosis said the Official Notice came from on November 24th from the Minister for Medical Care in the Netherlands – the competent authority Gnosis had lodged the application with.
Approval opens the door to the commercialisation of Mythocondro in the overall EU, and is a key milestone for Gnosis’ strategic global plan for the ingredient – which started in the USA with the granted GRAS Status of Mythocondro and initial commercialisation of the first products with the novel ingredient in 2017.
The new notice now allows for the approval for the placing of Chondroitin Sulfate (Mythocondro) on the market in the EU pursuant to Regulation (EC) No. 258/97 Article 4.2 first indent, said the firm.
“This achievement represents an important step forward for our company that has strenuously believed in this project since its beginnings,” commented said Marco Berna, Business Development Director of Gnosis.
“Today, within the nutraceuticals industry, CS is acknowledged as one of the most adulterated supplements in the market,” he added. “Mythocondro promises to change entirely the CS market, because it is the first Non-Animal Chondroitin Sulfate obtained through a fermentation-based manufacturing process, developed and patented by using a pharmaceutical approach, ensuring strict quality standards and providing a reliable and reproducible source of CS, able to definitely solve concerns related to poor quality of animal derived CS.”
Gnosis said the first supplements containing its vegetarian and vegan chondroitin sulfate will ‘finally’ be shipped in the EU markets at the start of 2018.